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Introduction
A n a t o m i c a l  r e s e c t i o n ,  p r i m a r i l y  l o b e c t o m y  o r 
segmentectomy is so far the best choice for treatment of 
stage I non-small-cell lung cancer (NSCLC) (1). It leads to 
5-year survival rates of 73% up to 94% for pathologic stage 
IA patients (2,3). According to several guidelines patients 
with impaired lung function are often precluded from 
this kind of pulmonary cancer resection (4-6). Operative 
mortality rates as high as 50% after lobectomy are reported 
in patients with NSCLC and severe emphysema (6,7). 
For these so-called medically inoperable patients, other 
treatment modalities are offered. Stereotactic ablative 
radiotherapy (SBRT) and radiofrequency ablation (RFA) 
have been proven to be effective in NSCLC in this subgroup 
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of patients (8,9). Three-year survival of 55.8% is reported. 
Patients with severe pulmonary emphysema are a particular 
subgroup of these inoperable patients. They represent a 
management problem to both the surgeon and the radiation 
oncologist, especially when surgeons are not experienced in 
LVRS. Anatomical resection focused on tumor resection only 
is often precluded due to the impaired lung function and 
even limited surgery itself is questioned. It can be considered 
only when the concepts of volume reduction are applied. 
Pneumothorax is a rare complication following radiation 
therapy but more frequent and carrying more morbidity in 
severe emphysema (10,11). Sublobar resection in form of 
wedge resections has not been clearly demonstrated to offer 
a better long-term oncological outcome in comparison to 
radiation therapy (12,13). Patients with severe emphysema 
and distinct functional criteria and emphysema distribution 
on computer tomography (CT) scan might benefit from 
sublobar cancer resection in a lung volume reduction 
surgery (LVRS) concept. In addition to resection of the 
tumor there is a high probability of improving lung function 
as health-related quality of life and physical exercise capacity 
in selected patients (14-18). All morphologies of emphysema 
are possibly approachable for LVRS (19,20). The aim of this 
retrospective study was to evaluate the functional and long 
term oncological outcome and morbidity and mortality of 
concomitant sublobar lung cancer resection and LVRS in 
selected patients.
Methods
Database search
The institution’s LVRS database was searched for patients 
who have undergone tumor resection in LVRS concept 
between 2003 and 2015.
Patient selection
Patients were mostly evaluated for LVRS and suspicious 
lung nodules or proven lung cancer were found. They 
were referred originally from external pulmonologists 
and discussed at our institutional tumor board with the 
question for appropriate diagnostic steps or treatment 
considering their impaired lung function. Inclusion 
criteria for LVRS were adapted from our modified patient 
selection criteria (21) (Table 1). Emphysema morphology 
was defined as following (22): markedly heterogeneous is 
defined as a distinct regional difference in the severity of 
emphysema in at least two adjacent lung segments of either 
lung. Intermediately heterogeneous is a distinct regional 
difference in severity of emphysema with a maximum in 
the area of one or more than one but not in adjacent lung 
segments of either lung. Homogeneous emphysema shows 
no regional or only minor differences in the severity of 
emphysema.
Patients with homogeneous emphysema morphology 
were not included for surgery in this series.
The resection was primarily indicated when the tumor 
was in a LVRS target zone, on the same side as the 
LVRS target zone or when it was considered resectable 
by ipsilateral segmentectomy or wedge combined with 
contralateral LVRS during the same operation.
Surgery
LVRS was performed unilaterally or bilaterally by video-
assisted thoracoscopic surgery (VATS) or by thoracotomy 
due to adhesions, if needed. For LVRS, the areas of 
pulmonary parenchyma exhibiting greatest destruction were 
resected with standard staplers (COVIDIEN Endo GIA™ 
Ultra Universal or ETHICON Echelon ENDOPATH™).
Table 1 Selection criteria for LVRS
Variable Inclusion Exclusion
Patient Nicotine abstention >4 months;  
passed pulmonary rehabilitation
Daily steroid intake >20 mg
CT morphology Lung emphysema Significant bronchiectasis
lung function FEV1 <45%, TLC >100%, RV >150% FEV1 <20% and diffusion capacity <20% in homogeneous emphysema
6-MWD <450 m –
Gas exchange – paCO2 >6.7 Pa, paO2 <6.0 Pa in homogeneous emphysema
6-MWD, 6 minutes walking distance; CT, computed tomography; FEV1, forced expiratory volume in 1 second; RV, residual volume; RV/
TLC, RV-TLC-ratio (= hyperinflation); TLC, total lung capacity.
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Follow up and outcome measures
All pulmonary lung function tests were performed using a 
standard body plethysmograph and CO diffusion capacity 
(Zahn, Germany). The follow up after three months was 
performed at our institution as a routine follow up after 
LVRS. The further follow up (survival) was performed with 
telephone contact to the family doctor and/or the patient 
itself. Tumors were staged according to the TNM system 
[7th edition, 2010 (23)].
Statistical analysis
Descriptive variables are expressed as median with range, 
counts with proportions or median and interquartile ranges 
(IQR), unless otherwise specified. Comparisons were done 
using the Wilcoxon matched-pair signed rank test. A P 
value of <0.05 was determined as significant. Kaplan-Meier 
estimation was used to depict survival.
All data and graphs were produced using SPSS (IBM 
Corp., Released 2013. IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, NY, USA).
Ethical approval
This study was approved by the Swiss local ethics 
committee (2016-0076).
Results
Fourteen patients (eight females, six males) were operated on. 
Median age at time of operation was 63 (range, 52–77) years.
Three procedures were bilateral (21%) and eleven 
unilateral. Eight have been performed by VATS (57%) and 
six with conversion to an open procedure due to adhesions. 
In ten patients, the tumor was resected atypically (71%) and 
in four patients with an anatomical segmental resection. All 
patients had lung volume reduction in addition (Table 2). 
Seven patients had heterogeneous emphysema (50%) and 
seven showed intermediate heterogeneous morphology. 
Only in three patients the cancer diagnosis was proven 
before operation.
UICC (Unité Internationale Contre Cancer) stage IA 
was confirmed in eleven patients (79%), stage IB in one 
patient and stage IV in one patient due to pleural metastasis. 
The sarcoma of the lung was not UICC staged (Table 2). 
Systematic lymph node dissection was performed only in 
two patients due to the severely impaired lung function in 
all patients. Therefore twelve patients had no pathological 
lymph node staging (86%). No patient had adjuvant 
chemotherapy or radiotherapy according to decisions at the 
institution’s tumor board.
Median hospitalization time was 9 (IQR, 7.75–12.5) days. 
Median postoperative drainage time was 6 (IQR, 4.75–8.25) 
days. Postoperative pneumothorax occurred in three 
patients (21%) after chest tube removal and required a new 
drain. Three patients (21%) had prolonged air leak longer 
than seven days and one of them needed re-operation for 
fistula closure. No other complications were reported. 
Perioperative 90-day mortality was zero, the patient with 
sarcoma died four months postoperatively.
Median pre-operative FEV1 predicted was 32.5% 
and improved significantly by 14% to a median FEV1 of 
37% three months postoperative (P=0.002). Decrease of 
hyperinflation (RV/TLC) was significant by 9%. The lung 
function values are listed in Table 3.
Follow up ranged from 6 to 126 months. Mean survival 
was 60 months (95% CI: 37.715–82.285 months, Figure 1). 
Three-year survival rate was 50% and five-year survival was 
36%. From the eight deceased patients, one died because 
of the tumor, five because of pulmonary non-cancer related 
reasons and in two patients the reason of death is unknown.
Discussion
This retrospective study describes concomitant LVRS with 
lung cancer resection at our institution. The results imply 
an improved functional outcome after cancer resection with 
low morbidity and mortality and good long-term-survival.
LVRS leads to several improvements and benefits in 
selected patients with emphysema (14,17,19,24), especially 
lung function improves and quality of life increases. 
Whereas anatomic lung resection offers the best long-
term-survival in early stage NSCLC most patients with 
severe emphysema are precluded from surgery due to 
impaired lung function (1,4,5,25). The latter is quoted 
in several international guidelines. However, several 
groups have reported their experience of combined lung 
cancer resection and LVRS which was done with the 
intention  to symptoms of severe emphysema and to offer 
resection of early-stage lung cancer especially also to get 
tissue for final diagnosis which was not confirmed prior 
to surgery. Already in 1996, McKenna et al. operated on 
eleven emphysema patients with lung cancer (seven wedge 
resections and four lobectomies both combined with 
bilateral LVRS) and reported a more than 100% increase 
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in FEV1% from pre- to postoperatively (26). Other studies 
mainly focused about lobectomies for cancer within an 
emphysematous lobe (27,28). Carretta et al. operated on 
10 patients and found significant functional improvement 
as well. Edwards et al. found no lung function changes 
three months postoperatively for patients with lobectomy 
of a poorly perfused and hyperinflated emphysematous 
lobe and pre-operative FEV1 less than 40% compared to 
a group with FEV1 greater than 40%. They concluded 
that standard calculations of pre-operative FEV1 may be 
misleading in emphysema patients and selection criteria 
might be extended in these selected patients. Choong et al. 
conducted a review on 21 patients with severe emphysema 
where nine underwent lobectomy alone and twelve had a 
Table 3 Lung function pre-operative and post-operative at 3 months
Variable Median preoperative, n=14 [IQR] Median postoperative at 3 months, n=14 [IQR] P value compared to preoperative
FEV1% 32.5 [27–37] 37.5 [32–48] 0.002
FEV1, mL 690 [597–850] 925 [780–1,093]
TLC % 117 [110–136] 108 [102–114] 0.014
TLC, mL 6,260 [5,480–8,500] 5,710 [5,060–7,200]
RV, % 187 [171–241] 147 [123–196] 0.002
RV, mL 4,010 [3,240–5,335] 3,020 [2,525–4,158]
RV/TLC, % 64 [62–70] 58 [54–62] 0.001
DLCO, % 30 [23–39] 32 [26–44] 0.116
DLCO, diffusion capacity; FEV1, forced expiratory volume in 1 second; IQR, interquartile range; mL, milliliters; RV, residual volume; RV/
TLC, RV-TLC-ratio (= hyperinflation); TLC, total lung capacity.
Table 2 Patient’s age, type of operation and cancer histology/stage
Age Operation Histology pTNM UICC stage
65 VATS bilateral LVRS upper lobes, open segment  
2 resection on the right side
Adenocarcinoma pT2 cN0–1 cM0 IA
59 VATS unilateral re-LVRS right upper lobe  
(VATS bilateral LVRS 3 years ago)
Large cell carcinoma pT2 cN0 cM0 IB
70 VATS unilateral LVRS right upper lobe Sarcoma of the lung pT1 cN0–1 CM0 –
63 Open LVRS right upper lobe Adenocarcinoma pT1 cN0 cM0 IA
63 Open lingula resection and LVRS right upper lobe Adenocarcinoma pT1 cN0 cM0 IA
69 Open segment 6 resection and LVRS right upper lobe Squamous cell carcinoma pT1 pN0 cM0 IA
69 VATS bilateral LVRS upper lobes Large cell carcinoma pT1a cN0 cM0 IA
77 VATS unilateral LVRS left upper lobe Squamous cell carcinoma pT1a cN0 cM0 IA
59 VATS unilateral LVRS right upper lobe Adenocarcinoma pT1a cN0 cM0 IA
63 VATS unilateral LVRS right upper lobe and middle lobe Adenocarcinoma pT1a cN0 cM0 IA
72 Open segment 6 resection and LVRS left lower lobe Squamous cell carcinoma pT1a pN0 cM0 IA
56 Open LVRS right upper lobe Adenocarcinoma pT2a pN0 pM1a (pleura) IV
58 VATS unilateral LVRS right upper lobe Large cell carcinoma pT1a cN0 M0 IA
52 VATS bilateral LVRS upper lobes Adenocarcinoma pT1a cN0 cM0 IA
LVRS, lung volume reduction surgery; VATS, video-assisted thoracic surgery.
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lobectomy [9] or a wedge resection [3] supplemented with 
LVRS (29). FEV1% predicted increased by 38% within six 
months postoperatively.
Recently, Makey and colleagues compared maximal 
oxygen consumption (VO2 max) values from the American 
College of Chest Physicians (ACCP) guidelines and from 
the National Emphysema Treatment Trial (NETT) 
homogeneous non-upper lobe predominant emphysema 
(NULPD) surrogate for predicting operative mortalities (30). 
The “high-risk” cohort (VO2 max <10 mL/kg/min) showed 
lower predicted operative risk for NSCLC resection than 
the ACCP guidelines. ACCP guidelines patients (27) had 
an operative mortality of 26% and NETT’s homogeneous 
NULPD patients (29) showed a mortality rate of 14%. 
Eight-year survival rates in both compared groups were 
similar suggesting that LVRS did not shorten life span at 
this time point in patients with severe emphysema.
With pre-operative median values of FEV1 of predicted 
32.5% and diffusion capacity of predicted 30% most of 
our patients might have been precluded from surgery and 
have undergone radiation therapy. Besides some theoretical 
research there is so far no evidence of lung volume reduction 
after radiation therapy (31). Our patient’s perioperative 
morbidity is very low and the only relevant complication 
after surgery is prolonged air leak. Three patients (21%) 
showed air leakage longer than seven days and one of 
them was re-operated for fistula closure. Prolonged air 
leak is a well-known issue after LVRS and ranges from 
30% in our own cohort up to 57% in literature (32). 
Linden and colleagues reported a 1% operative mortality 
rate from sublobar resection of lung tumors in 96 
consecutive patients with preoperative FEV1 less than 35% 
of predicted (33). The 90-day mortality in our patients 
was zero and might be a reflection of our long-lasting 
experience in treating emphysema patients. Patients had to 
fulfill our selection criteria for LVRS (Table 1).
Five-year survival rate was 36% which is lower than in 
previous reported series (62.7%) but most operations by 
Choong et al. were performed as anatomical resections (29). 
Lobectomy is still the standard of resection for lung cancer.
As limitation, this is a small retrospective review of highly 
selected patients and lung function follow-up values are 
only available for the first three months after operation. All 
potentially eligible patients for LVRS should be discussed at 
a multidisciplinary emphysema board at highly experienced 
centers (34). Therefore, indication is still the key issue and 
even in prospective trials only carefully selected patients will 
experience concomitant cancer resection and LVRS.
Primary radiation therapy might be proposed for patients 
with emphysema, impaired lung function and NSCLC 
but this strategy lacks the beneficial effect of lung volume 
reduction. Radiation therapy shows only few complications 
[i.e., pneumonitis (35)] but our patients after concomitant 
cancer resection and LVRS profit from low morbidity as 
well. LVRS is safe and effective in all types of emphysema 
morphology and therefore cancer resection heterogeneous 
and even in intermediately heterogeneous emphysema 
should be taken into account (18,20,36). Again, one should 
observe standard selection criteria for LVRS.
From an oncological point of view sublobar resections 
are at least comparable with radiation therapy and therefore 
overall survival might be similar (8,9). Three-year survival 
of 55.8% and 2-year survival of 73% after radiation therapy 
is comparable with the 3-year survival of 50% and the 5-year 
survival of 36% in our patients. This comparison must be 
considered with caution as our study counts only on highly 
selected patients.
In conclusion, sublobar resection of early stage 
lung cancer combined with LVRS in patients with 
severe emphysema improves lung function and shows 
low morbidity and mortality. Oncological outcome is 
comparable to radiation therapy which lacks the beneficial 
effect of LVRS. Patient selection plays a key role and 
therefore lung cancer patients with emphysema should be 
discussed at a tumor board including thoracic surgeons with 
experience in LVRS or be presented at a multidisciplinary 
emphysema board.
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